UNSPSC 51131610: Ardeparin

This classification denotes a low molecular weight heparin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N3927D01PB. European Medicines Agency schedules Ardeparin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00574MIG. Ardeparin sodium generally arises in the molecular formula (C14H18NO11)N.2(C12H15NO13S)N.3NA.3O3S.

The term ARDEPARIN SODIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33.) As of Q4 2014, ARDEPARIN remains the US FDA Preferred Term for this commodity. SMILES: C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-].

UNSPSC 51131610 Ardeparin is a Commodity code that nominally covers a specific anticoagulant pharmaceutical product, but the recent state and local procurement activity tagged to this code does not reflect pharmaceutical procurement. The sole recent opportunity posted under this code is Sourcewell RFP #061626, issued on behalf of the State of Minnesota local government unit and service cooperative on May 12, 2026, which solicits Law Enforcement Equipment for participating governmental entities across multiple states and Canadian jurisdictions. This mismatch between the code's pharmaceutical scope and the actual procurement being tagged suggests either a classification error in the opportunity posting or that the code assignment does not align with what state and local governments are actually buying under this UNSPSC number in current market activity.

Given the absence of additional recent opportunities under UNSPSC 51131610 that reflect ardeparin or related anticoagulant products, the code shows limited relevant procurement activity for business development professionals focused on pharmaceutical supply or related medical-product lines. The single tagged opportunity—Sourcewell's law-enforcement-equipment RFP with a June 16, 2026 response deadline—does not represent meaningful activity for vendors in the anticoagulant or pharmaceutical supply sectors. State and local procurement activity under this code does not support a pursuit strategy at this time.